CRL vs. HALO: Charles River Laboratories vs. Halozyme Therapeutics Stock Comparison

Company Profile

Charles River Laboratories (CRL) and Halozyme Therapeutics (HALO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but CRL is classified in Life Sciences Tools & Services while HALO is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Halozyme Therapeutics (HALO) at 216.38% clears its industry range for ROE, a sharper capital-efficiency signal than Charles River Laboratories (CRL) at 1.27%, which is closer to a typical peer reading.

Halozyme Therapeutics (HALO) at 26.93% converts revenue to bottom-line profit above its industry’s benchmark range, while Charles River Laboratories (CRL) at 1.01% keeps roughly the typical share for its industry.

Both Charles River Laboratories (CRL) at 23.42% and Halozyme Therapeutics (HALO) at 59.84% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Halozyme Therapeutics (HALO) at 37.55% is around its peer norm for revenue growth, while Charles River Laboratories (CRL) at -0.85% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Halozyme Therapeutics (HALO) at -25.36% is around its peer norm for EPS growth, while Charles River Laboratories (CRL) at -1,555.00% falls below its industry range, a notably weak earnings reading.

Growth Metrics

Financial Strength

Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while Charles River Laboratories (CRL) at 1.41 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for CRL.

Only one side’s leverage can be read here: Charles River Laboratories (CRL) carries debt-to-equity ratio of 0.87 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

Financial Strength Metrics

Dividends

Neither Charles River Laboratories (CRL) nor Halozyme Therapeutics (HALO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Charles River Laboratories (CRL) nor Halozyme Therapeutics (HALO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Halozyme Therapeutics (HALO) at 25.91 is near its industry’s usual P/E ratio, while Charles River Laboratories (CRL) at 366.87 sits above its peer range — an unusually expensive price for CRL’s trailing earnings.

On P/S ratio, both Charles River Laboratories (CRL) at 4.07 and Halozyme Therapeutics (HALO) at 6.55 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Charles River Laboratories (CRL) reports 5.01, ranking against industry peers normally.

Valuation Metrics